HK Stock Market Move | INSILICO (03696) rises over 5%, plans to repurchase up to HK$500 million worth of shares in the open market; positive ISM6331 data recently presented at ESMO

INSILICO (03696) rose over 5%, up 4.67% as of press time at HK$37.68, with turnover of HK$248 million. On the news front, on October 30, INSILICO announced that the company has decided, under the general mandate (repurchase mandate) granted to the directors at the annual general meeting held on June 2, 2026 and approved by the company's shareholders, to repurchase its shares from time to time on the open market of The Stock Exchange of Hong Kong Limited (the Stock Exchange), with an aggregate amount of up to HK$500 million (the share repurchase). The board believes that the current trading price of the shares undervalues the company's intrinsic value and development prospects, and that the share repurchase will enhance shareholder value. The share repurchase reflects the company's confidence in its business prospects and development, and will benefit the company and create value for its shareholders in the long run. Recently, INSILICO announced that the company has recently published preliminary positive data from the first-in-human Phase I clinical trial of ISM6331. ISM6331 is an investigational oral pan-TEAD inhibitor designed with the empowerment of the Chemistry42 generative AI platform. The research results were presented in a rapid oral presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress held in Madrid, Spain. In preclinical studies, ISM6331 demonstrated broad antitumor efficacy, potent activity at low doses, a favorable safety profile, and good ADMET properties. Previously, in July 2026, ISM6331 received Fast Track designation from the FDA.